Literature DB >> 24828991

Management of Atrial Fibrillation.

Payman Zamani1, Ralph J Verdino2.   

Abstract

Atrial fibrillation remains the most prevalent cardiac arrhythmia, and its incidence is increasing as the population ages. Common conditions associated with an increased incidence include advanced age, hypertension, heart failure, and valvular heart disease. Patients with atrial fibrillation may complain of palpitations, fatigue, and decreased exercise tolerance or may be completely asymptomatic. Options for treating patients who experience atrial fibrillation include rate-controlling drugs such as digoxin, β-blockers, and calcium channel blockers or a rhythm-controlling strategy with agents such as sodium channel blockers and potassium channel blockers. Atrial fibrillation increases the risk of stroke due to atrial thrombus formation and embolization. Anticoagulation with the vitamin K antagonist, warfarin, remains the most widely prescribed treatment option to decrease stroke risk. Several other antithrombotic agents have recently become available and offer excellent alternatives to warfarin. Catheter ablation can be undertaken as a nonpharmacologic rhythm control option with varying degrees of success depending on duration of atrial fibrillation and follow-up time from the procedure. This review article further describes the management options for patients presenting with atrial fibrillation.
© The Author(s) 2014.

Entities:  

Keywords:  antiarrhythmic drugs; antithrombotic drugs; atrial fibrillation; catheter ablation

Mesh:

Substances:

Year:  2014        PMID: 24828991     DOI: 10.1177/0885066614534603

Source DB:  PubMed          Journal:  J Intensive Care Med        ISSN: 0885-0666            Impact factor:   3.510


  2 in total

1.  Nonlinear relationship between serum total bilirubin levels and initial ischemic stroke in patients with non-valvular atrial fibrillation.

Authors:  Ying Liu; Jie Wang; Wen-Zhen Zeng; Qing-Shan Lyu
Journal:  J Int Med Res       Date:  2020-10       Impact factor: 1.671

2.  Benefits of prescribing low-dose digoxin in atrial fibrillation.

Authors:  Ciprian Ilie Rosca; Nilima Rajpal Kundnani; Anca Tudor; Maria-Silvia Rosca; Violeta-Ariana Nicoras; Gabriela Otiman; Elena Ciurariu; Alin Ionescu; Morariu Stelian; Abhinav Sharma; Claudia Borza; Daniel Florin Lighezan
Journal:  Int J Immunopathol Pharmacol       Date:  2021 Jan-Dec       Impact factor: 3.219

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.